Plus Therapeutics Successfully Completes Key Milestone for cGMP Manufacture of Lead Investigational Radiotherapeutic
12 juil. 2022 07h00 HE
|
Plus Therapeutics Inc.
Completes technology transfer and initiates cGMP manufacturing for critical Rhenium-186 NanoLiposome (186RNL) drug product intermediate On track to manufacture cGMP materials to support ongoing and...
Plus Therapeutics and Biocept Announce Comprehensive Laboratory Services Agreement for the ReSPECT-LM Trial
22 juin 2022 07h30 HE
|
Plus Therapeutics Inc.
Biocept’s CNSide™ assay provides a highly sensitive method to assess and quantify tumor cell burden in leptomeningeal metastasis (LM) of the central nervous system Assay results will be used to...
Plus Therapeutics Completes Enrollment of Cohort 1 ReSPECT-LM Phase 1/2a Trial
16 juin 2022 07h30 HE
|
Plus Therapeutics Inc.
Rhenium-186 NanoLiposome (186RNL) Targeted Radiotherapeutic successfully delivered without dose limiting toxicities in initial cohort Next step: Data Safety & Monitoring Board to consider further...
Plus Therapeutics Reports Positive Clinical Outcomes from ReSPECT-GBM Trial at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting
13 juin 2022 07h05 HE
|
Plus Therapeutics Inc.
Data validates continued high radiation absorbed of 186RNL in escalating doses to treat glioblastoma, maintaining safety and limiting brain and whole-body exposure Company will also present at...
Plus Therapeutics to Present Virtually at the 2022 HC Wainwright Global Investment Conference
18 mai 2022 07h00 HE
|
Plus Therapeutics Inc.
AUSTIN, Texas, May 18, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and...
Plus Therapeutics to Present at the 2022 Q2 Investor Summit
26 avr. 2022 07h00 HE
|
Plus Therapeutics Inc.
AUSTIN, Texas, April 26, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and...
Plus Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
21 avr. 2022 16h05 HE
|
Plus Therapeutics Inc.
First patient dosed in ReSPECT-LM Phase 1/2a dose escalation trial of 186RNL for leptomeningeal metastases Closed in-licensing transaction for novel targeted radioembolic...
Plus Therapeutics Announces Oral Presentation at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting
19 avr. 2022 07h00 HE
|
Plus Therapeutics Inc.
AUSTIN, Texas, April 19, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics...
Plus Therapeutics to Announce First Quarter 2022 Financial Results and Host Conference Call on April 21, 2022
14 avr. 2022 07h00 HE
|
Plus Therapeutics Inc.
AUSTIN, Texas, April 14, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics...
Plus Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting
08 avr. 2022 16h05 HE
|
Plus Therapeutics Inc.
AUSTIN, Texas, April 08, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics...